Innova Captab Q3 FY26 Earnings Analysis

- Innova Captab targets 20%+ top-line growth over the next 3-4 years, aiming to double revenue as per past trends. - The Jammu facility is planned to ramp up over a 3-4 year horizon, targeting north of INR 1,400 crores revenue at 65-70% capacity utilization. - Current Jammu revenue is around INR 120 crores for H1 FY26, targeting approximately INR 270-280 crores for full FY26, below the initial INR 400 crores estimate due to API price correction. - CDMO business is witnessing 15% YoY growth in Q2 FY26, supported by expanding client base and product portfolio. - Branded Generics segment shows strong growth at 31% YoY in Q2 FY26 and 43% in H1 FY26. - Volume growth in manufacturing (excluding Jammu) is around 8-10% despite a 10-12% price decline. - Outlook remains positive with expectations of price stabilization and continued operational efficiencies supporting growth.

- Innova Captab aims to double its top line in the next 3 to 4 years, targeting a 20%+ annual growth trajectory. - EBITDA margin is expected to stabilize around 15% in the long term, despite short-term margin pressures from GST reduction. - The Jammu facility ramp-up is planned over 3-4 years, targeting INR1,400+ crores revenue at 65-70% utilization. - Short-term margin may be impacted due to GST reworking from 12% to 5%, but long-term margins are expected to sustain at ~15% once efficiencies improve. - EBITDA breakeven is near for Jammu, with reassessment ongoing due to GST changes. - Overall, management remains optimistic about sustaining growth momentum, operational efficiency, and long-term value creation for stakeholders.

- Innova Captab invested approximately INR480 crores in the Jammu facility. - The Jammu plant is expected to reach 65%-70% capacity utilization within 3-4 years. - Peak revenue potential from Jammu is estimated at north of INR1,400 crores. - Jammu expansion is a key part of the 20%+ growth trajectory and is expected to contribute significantly to future growth. - The company is reassessing EBITDA levels and breakeven timelines for Jammu in light of GST changes; breakeven is nearing at current turnover. - No specific mention of additional new capex or strategic investments beyond Jammu was disclosed in this call.

- No specific mention of any current or future fundraising through debt or equity was made during the earnings call. - The management did not discuss plans for raising capital via debt or equity in the Q2 & H1 FY26 earnings call held on November 10, 2025. - Focus was on operational growth, margin sustainability, and capacity ramp-up, especially related to the Jammu facility. - No direct guidance or indication was provided regarding fundraising activities in the near term.

- Innova Captab has a strong order book, which is expected to support growth in the coming months. - The company is optimistic about sustaining growth momentum due to this robust pipeline. - Several prominent pharmaceutical companies have completed audits and reviews at the new Jammu facility, with business operations commenced with some and advanced discussions ongoing with others. - This strong foundation is expected to enable scale-up in the near term. - The continuing operational efficiency and possible stabilization in API prices further support the outlook. - Overall, the firm is focused on maintaining high service quality and deepening client relationships to leverage the order book for consistent value creation.